ValuEngine Downgrades Bayer (OTCMKTS:BAYRY) to Strong Sell

ValuEngine lowered shares of Bayer (OTCMKTS:BAYRY) from a sell rating to a strong sell rating in a research note issued to investors on Monday, April 1st, ValuEngine reports.

A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. downgraded Bayer from an overweight rating to a neutral rating in a report on Wednesday, January 2nd. Deutsche Bank downgraded Bayer from a buy rating to a hold rating in a report on Sunday, March 31st. Zacks Investment Research upgraded Bayer from a strong sell rating to a hold rating in a report on Wednesday, February 13th. Bryan, Garnier & Co downgraded Bayer from a neutral rating to a sell rating in a report on Thursday, March 28th. Finally, Berenberg Bank initiated coverage on Bayer in a report on Monday, April 1st. They set a hold rating for the company. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. Bayer currently has a consensus rating of Hold.

BAYRY traded down $0.56 during midday trading on Monday, hitting $16.80. The stock had a trading volume of 324,552 shares, compared to its average volume of 937,418. The firm has a market cap of $62.74 billion, a P/E ratio of 9.60, a P/E/G ratio of 0.85 and a beta of 0.92. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.59 and a quick ratio of 1.04. Bayer has a 1 year low of $15.67 and a 1 year high of $32.80.

Bayer (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, February 27th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.05. The business had revenue of $12.62 billion during the quarter. Bayer had a return on equity of 12.39% and a net margin of 4.74%. On average, equities analysts anticipate that Bayer will post 1.95 earnings per share for the current year.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Price-Sales Ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bayer (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with's FREE daily email newsletter.